CPHRF Stock — Cipher Pharmaceuticals Inc

Cipher Pharmaceuticals Inc (CPHRF)

Updated October 16, 2026.

CPHRF is a Stock. Total return is 208.8% over the past 20.7 years, 558.1 points behind SPY at 766.9%.

Cipher Pharmaceuticals is a Canadian specialty pharmaceutical company that develops and commercializes dermatological, pain management, and cardiovascular products, including branded medications such as Epuris and Actikerall for skin conditions, Durela for pain relief, and Brinavess for atrial fibrillation, along with pipeline candidates in areas including psoriasis and tattoo removal. The company's distribution profile is not currently known. This security may appeal to investors seeking exposure to specialty pharmaceuticals and Canadian healthcare, though potential investors should evaluate the company's clinical pipeline and commercial execution independently.

CPHRF performance versus SPY

Price and return data through 2026-10-16.

Total return is 208.8% over the past 20.7 years, 558.1 points behind SPY at 766.9%. Over the past year its total return — price change plus distributions reinvested — is -10.8%. Its deepest 1-year drawdown was 34.1%.

CPHRF key facts

Asset type

Stock

Asset class

Equity

Inception date

01/27/2006

Distribution frequency

None

Last close

$9.45 (as of 2026-10-16)

Market cap

$240,172,430

Average volume

1400.0

Beta

0.414

Payout ratio

0.0%

P/E ratio

8.51

Forward P/E

11.2994

EPS

$1.11

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

CPHRF risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 34.1%.

Who may consider CPHRF — and who may not

It is a weaker fit for investors who need monthly cash flow (CPHRF does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on CPHRF

• All tickers starting with C

Tagged: Healthcare.

Frequently asked questions